Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
04:15pm, Tuesday, 17'th Feb 2026
DUBLIN, Feb. 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor conferences: TD Cowen 46th Annual Health Care
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Tuesday, 17'th Feb 2026
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock?
09:41am, Wednesday, 11'th Feb 2026
Investors need to pay close attention to Jazz Pharmaceuticals stock based on the movements in the options market lately.
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
04:15pm, Tuesday, 10'th Feb 2026
DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the c
Principal Financial Group Inc. Decreases Stock Position in Jazz Pharmaceuticals PLC $JAZZ
04:52am, Monday, 09'th Feb 2026
Principal Financial Group Inc. lowered its position in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 3.6% in the undefined quarter, according to the company in its most recent filing with the SEC. The fu
Universal Beteiligungs und Servicegesellschaft mbH Cuts Position in Jazz Pharmaceuticals PLC $JAZZ
06:20am, Monday, 26'th Jan 2026
Universal Beteiligungs und Servicegesellschaft mbH decreased its position in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 15.0% during the undefined quarter, according to the company in its most recent
4,593 Shares in Jazz Pharmaceuticals PLC $JAZZ Purchased by Sequoia Financial Advisors LLC
05:36am, Monday, 26'th Jan 2026
Sequoia Financial Advisors LLC bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) during the undefined quarter, according to its most recent filing with the SEC. The institutio
Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:16pm, Tuesday, 13'th Jan 2026
Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Recommendation of “Moderate Buy” by Brokerages
02:14am, Tuesday, 13'th Jan 2026
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ - Get Free Report) has been given an average rating of "Moderate Buy" by the seventeen research firms that are currently covering the company, MarketBeat.com rep
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategi
Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript
02:24pm, Friday, 09'th Jan 2026
Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology
01:46pm, Friday, 09'th Jan 2026
Jazz Pharmaceuticals plc is deeply undervalued, trading at 2.4x sales, as the market overlooks its oncology pivot and robust growth catalysts. Ziihera's Phase 3 data surpassing Herceptin signals a tra
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
04:05pm, Thursday, 08'th Jan 2026
Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNewswire/ --
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial
01:12pm, Wednesday, 07'th Jan 2026
Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years.
Positive Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standar
